Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Nurix Therapeutics (NRIX) Accumulated Depreciation & Amortization (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $39.7 million as the latest value for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 8.05% to $39.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $39.7 million through Feb 2026, up 8.05% year-over-year, with the annual reading at $8.7 million for FY2025, 6.02% down from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $39.7 million at Nurix Therapeutics, up from $8.7 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $40.7 million in Q3 2025, with the low at $1.8 million in Q1 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $20.7 million, with a median of $18.2 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization plummeted 88.85% in 2023, then skyrocketed 1697.75% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $5.3 million in 2022, then soared by 42.13% to $7.5 million in 2023, then grew by 23.46% to $9.3 million in 2024, then decreased by 6.02% to $8.7 million in 2025, then soared by 354.51% to $39.7 million in 2026.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $39.7 million, $8.7 million, and $40.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.